METHOD OF INDUCING NEGATIVE CHEMOTAXIS
The current invention is directed to methods of inducing the negative chemotaxis of a migratory cell comprising contacting the cell with a compound selected from the group consisting of idebenone, benazepril, rolipram, moxonidine, lamivudine, loxoprofen, terbinafine, synephrine, 6-aminoindazole, and a Vitamin D analog, or a pharmaceutically acceptable salt of any of thereof.
1 . A method of inducing negative chemotaxis of a human migratory cell comprising administering an effective amount of a compound selected from the group consisting of idebenone, benazepril, rolipram, moxonidine, lamivudine, loxoprofen, terbinafine, synephrine, 6-aminoindazole and a Vitamin D analog, or a pharmaceutically acceptable salt of any of thereof.
2 . The method of claim 1 , wherein the human migratory cell is an immune cell.
3 . The method of claim 2 , wherein the immune cell is selected from the group consisting of lymphocytes, monocytes, neutrophils, eosinophils, and mast cells.
4 . The method of claim 3 , wherein the immune cell is a neutrophil.
5 . The method of claim 3 , wherein the immune cell is an eosinophil.
6 . The method of claim 1 , wherein the compound is idebenone.
7 . The method of claim 1 , wherein the compound is benazepril.
8 . The method of claim 7 , wherein the compound is benazepril hydrochloride.
9 . The method of claim 1 , wherein the compound is rolipram.
10 . The method of claim 1 , wherein the compound is moxonidine.
11 . The method of claim 10 , wherein the compound is moxonidine hydrochloride.
12 . The method of claim 1 , wherein the compound is lamivudine.
13 . The method of claim 1 , wherein the compound is a Vitamin D analog.
14 . The method of claim 13 , wherein the Vitamin D analog is selected from the group consisting of calcitriol, calcipotriol, ergocalciferol and cholecalciferol.
15 . The method of claim 14 , wherein the Vitamin D analog is calcitriol.
16 . The method of claim 1 , wherein the compound is loxoprofen.
17 . The method of claim 16 , wherein the compound is loxoprofen sodium.
18 . The method of claim 1 , wherein the compound is terbinafine.
19 . The method of claim 18 , wherein the compound is terbinafine hydrochloride.
20 . The method of claim 1 , wherein the compound is Synephrine.
21 . The method of claim 1 , wherein the compound is 6-aminoindazole.
22 . The method of claim 1 , wherein chemotaxis toward a site of inflammation is inhibited.
23 . The method of claim 1 , wherein chemotaxis toward a medical implant is inhibited.
24 . The method of claim 1 , wherein chemotaxis toward a site of angiogenesis is inhibited.
25 . A method of inhibiting the chemotactic induction of an immune cell in a patient in need thereof comprising administering to said patient a therapeutically effective amount of a compound selected from the group consisting of idebenone, benazepril, rolipram, moxonidine, lamivudine, loxoprofen, terbinafine, synephrine, 6-aminoindazole and a Vitamin D analog, or a pharmaceutically acceptable salt of any of thereof.
26 . The method of claim 25 , wherein the patient is suffering from an inflammatory condition.
27 . The method of claim 25 , wherein the compound is administered locally to the site of inflammation.
28 . The method of claim 26 , wherein the inflammatory condition is injection site reaction.
29 . The method of claim 25 , wherein the patient is suffering from cancer or a tumor and angiogenesis is inhibited.
30 . The method of claim 25 , wherein chemotactic induction of an immune cell toward a medical implant is inhibited.
31 . The method of claim 30 , wherein the compound is administered by coating a surface of the medical implant.
32 . The method of claim 30 , wherein the compound is administered locally at the site of the medical implant.
33 . The method of claim 25 , wherein chemotactic induction of an immune cell toward a transplant or graft is inhibited.